Novo Nordisk seeks to block compounded Victoza
Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
FiercePharma2d
Novo asks FDA to restrict Victoza compounding amid GLP-1 outsourcing row
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
hemophilianewstoday2d
FDA approves Alhemo for hemophilia A or B with inhibitors
The U.S. FDA has approved Alhemo, given as once-daily injections, to help prevent bleeds in patients with hemophilia A or B ...
verywellhealth2d
Another Study Links Ozempic to a Rare Eye Condition That Can Cause Vision Loss
A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...
MedCity News2d
FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.
BioPharma Dive3d
FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...